|Other Names||Cytosolic beta-glucosidase, Cytosolic beta-glucosidase-like protein 1, GBA3, CBG, CBGL1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Glycosidase probably involved in the intestinal absorption and metabolism of dietary flavonoid glycosides. Able to hydrolyze a broad variety of glycosides including phytoestrogens, flavonols, flavones, flavanones and cyanogens. Possesses beta- glycosylceramidase activity and may be involved in a nonlysosomal catabolic pathway of glycosylceramide.|
|Cellular Location||Cytoplasm, cytosol|
|Tissue Location||Present in small intestine (at protein level). Expressed in liver, small intestine, colon, spleen and kidney Down-regulated in renal cell carcinomas and hepatocellular carcinomas.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
GBA3, or cytosolic beta-glucosidase (EC 22.214.171.124), is apredominantly liver enzyme that efficiently hydrolyzesbeta-D-glucoside and beta-D-galactoside, but not any knownphysiologic beta-glycoside, suggesting that it may be involved indetoxification of plant glycosides (de Graaf et al., 2001 [PubMed11389701]). GBA3 also has significant neutral glycosylceramidaseactivity (EC 126.96.36.199), suggesting that it may be involved in anonlysosomal catabolic pathway of glucosylceramide metabolism(Hayashi et al., 2007 [PubMed 17595169]).
Dekker, N., et al. Blood Cells Mol. Dis. (2010) In press :Noguchi, J., et al. Biochem. Biophys. Res. Commun. 374(3):549-552(2008)Hayashi, Y., et al. J. Biol. Chem. 282(42):30889-30900(2007)Tribolo, S., et al. J. Mol. Biol. 370(5):964-975(2007)Beutler, E., et al. J. Lab. Clin. Med. 144(2):65-68(2004)
If you have any additional inquiries please email technical services at email@example.com.